Cargando…

Mini-review of kidney disease following hematopoietic stem cell transplant


Advancements in hematopoietic cell transplantation (HCT) have broadened indications for its use and resulted in more long-term survivors. Stem cell transplantation is associated with several well-known toxicities, although renal complications are not well defined. Acute and chronic kidney disease re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sedhom, Ramy, Sedhom, Daniel, Jaimes, Edgar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727568/
https://www.ncbi.nlm.nih.gov/pubmed/29578399
http://dx.doi.org/10.5414/CN109276

_version_ 1783449279835144192
author Sedhom, Ramy
Sedhom, Daniel
Jaimes, Edgar
author_facet Sedhom, Ramy
Sedhom, Daniel
Jaimes, Edgar
author_sort Sedhom, Ramy
collection PubMed
description Advancements in hematopoietic cell transplantation (HCT) have broadened indications for its use and resulted in more long-term survivors. Stem cell transplantation is associated with several well-known toxicities, although renal complications are not well defined. Acute and chronic kidney disease remains a common complication following transplantation itself. Incidence and risk factors for the development of chronic kidney disease (CKD) is less well understood. Recent estimates suggest that nearly 15% of subjects undergoing HCT will develop CKD, a complication that can progress to end-stage renal disease (ESRD), disrupts overall quality of life, and reduces overall survival. Several commonly-reported risk factors include acute kidney injury, graft-versus-host disease, and long-term calcineurin inhibitor use. This review highlights the incidence, timeline, etiology, risk factors, and prognosis of kidney disease in the setting of hematopoietic stem cell transplantation. Investigation of the causes of CKD is needed, as are ways to prevent, mitigate, and treat kidney injury. Renal disease importantly reflects prognosis, with dialysis-requiring patients carrying greater than 80% mortality after 3 years. Although CKD following HCT is common, prospective studies are needed to confirm risk factors and better define the underlying mechanisms in order to promote therapies that prevent this complication.

format Online
Article
Text
id pubmed-6727568
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-67275682019-10-30 Mini-review of kidney disease following hematopoietic stem cell transplant
 Sedhom, Ramy Sedhom, Daniel Jaimes, Edgar Clin Nephrol Review Article Advancements in hematopoietic cell transplantation (HCT) have broadened indications for its use and resulted in more long-term survivors. Stem cell transplantation is associated with several well-known toxicities, although renal complications are not well defined. Acute and chronic kidney disease remains a common complication following transplantation itself. Incidence and risk factors for the development of chronic kidney disease (CKD) is less well understood. Recent estimates suggest that nearly 15% of subjects undergoing HCT will develop CKD, a complication that can progress to end-stage renal disease (ESRD), disrupts overall quality of life, and reduces overall survival. Several commonly-reported risk factors include acute kidney injury, graft-versus-host disease, and long-term calcineurin inhibitor use. This review highlights the incidence, timeline, etiology, risk factors, and prognosis of kidney disease in the setting of hematopoietic stem cell transplantation. Investigation of the causes of CKD is needed, as are ways to prevent, mitigate, and treat kidney injury. Renal disease importantly reflects prognosis, with dialysis-requiring patients carrying greater than 80% mortality after 3 years. Although CKD following HCT is common, prospective studies are needed to confirm risk factors and better define the underlying mechanisms in order to promote therapies that prevent this complication.
 Dustri-Verlag Dr. Karl Feistle 2018-06 2018-03-26 /pmc/articles/PMC6727568/ /pubmed/29578399 http://dx.doi.org/10.5414/CN109276
 Text en © Dustri-Verlag Dr. K. Feistle http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Sedhom, Ramy
Sedhom, Daniel
Jaimes, Edgar
Mini-review of kidney disease following hematopoietic stem cell transplant

title Mini-review of kidney disease following hematopoietic stem cell transplant

title_full Mini-review of kidney disease following hematopoietic stem cell transplant

title_fullStr Mini-review of kidney disease following hematopoietic stem cell transplant

title_full_unstemmed Mini-review of kidney disease following hematopoietic stem cell transplant

title_short Mini-review of kidney disease following hematopoietic stem cell transplant

title_sort mini-review of kidney disease following hematopoietic stem cell transplant

topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727568/
https://www.ncbi.nlm.nih.gov/pubmed/29578399
http://dx.doi.org/10.5414/CN109276

work_keys_str_mv AT sedhomramy minireviewofkidneydiseasefollowinghematopoieticstemcelltransplant
AT sedhomdaniel minireviewofkidneydiseasefollowinghematopoieticstemcelltransplant
AT jaimesedgar minireviewofkidneydiseasefollowinghematopoieticstemcelltransplant